nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.00155	0.00156	CcSEcCtD
Apraclonidine—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.00155	0.00156	CcSEcCtD
Apraclonidine—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.00155	0.00156	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Zidovudine—acquired immunodeficiency syndrome	0.00155	0.00156	CcSEcCtD
Apraclonidine—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00155	0.00156	CcSEcCtD
Apraclonidine—Palpitations—Delavirdine—acquired immunodeficiency syndrome	0.00155	0.00155	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.00155	0.00155	CcSEcCtD
Apraclonidine—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.00154	0.00155	CcSEcCtD
Apraclonidine—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.00154	0.00155	CcSEcCtD
Apraclonidine—Discomfort—Efavirenz—acquired immunodeficiency syndrome	0.00154	0.00155	CcSEcCtD
Apraclonidine—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.00154	0.00155	CcSEcCtD
Apraclonidine—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.00154	0.00154	CcSEcCtD
Apraclonidine—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.00153	0.00154	CcSEcCtD
Apraclonidine—Paraesthesia—Zidovudine—acquired immunodeficiency syndrome	0.00152	0.00153	CcSEcCtD
Apraclonidine—Dysgeusia—Saquinavir—acquired immunodeficiency syndrome	0.00152	0.00153	CcSEcCtD
Apraclonidine—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	0.00152	0.00153	CcSEcCtD
Apraclonidine—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.00152	0.00153	CcSEcCtD
Apraclonidine—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.00152	0.00153	CcSEcCtD
Apraclonidine—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.00151	0.00152	CcSEcCtD
Apraclonidine—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.00151	0.00152	CcSEcCtD
Apraclonidine—Ill-defined disorder—Ritonavir—acquired immunodeficiency syndrome	0.0015	0.00151	CcSEcCtD
Apraclonidine—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.00149	0.0015	CcSEcCtD
Apraclonidine—Chest pain—Delavirdine—acquired immunodeficiency syndrome	0.00149	0.0015	CcSEcCtD
Apraclonidine—Myalgia—Delavirdine—acquired immunodeficiency syndrome	0.00149	0.0015	CcSEcCtD
Apraclonidine—Erythema—Lamivudine—acquired immunodeficiency syndrome	0.00149	0.00149	CcSEcCtD
Apraclonidine—Discomfort—Delavirdine—acquired immunodeficiency syndrome	0.00147	0.00148	CcSEcCtD
Apraclonidine—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00147	0.00147	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.00147	0.00147	CcSEcCtD
Apraclonidine—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.00146	0.00147	CcSEcCtD
Apraclonidine—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.00146	0.00147	CcSEcCtD
Apraclonidine—Malaise—Ritonavir—acquired immunodeficiency syndrome	0.00146	0.00147	CcSEcCtD
Apraclonidine—Tension—Lamivudine—acquired immunodeficiency syndrome	0.00146	0.00147	CcSEcCtD
Apraclonidine—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.00146	0.00146	CcSEcCtD
Apraclonidine—Dysgeusia—Lamivudine—acquired immunodeficiency syndrome	0.00145	0.00146	CcSEcCtD
Apraclonidine—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.00145	0.00146	CcSEcCtD
Apraclonidine—Pain—Zidovudine—acquired immunodeficiency syndrome	0.00145	0.00146	CcSEcCtD
Apraclonidine—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.00145	0.00146	CcSEcCtD
Apraclonidine—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.00145	0.00146	CcSEcCtD
Apraclonidine—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.00145	0.00146	CcSEcCtD
Apraclonidine—Ill-defined disorder—Saquinavir—acquired immunodeficiency syndrome	0.00144	0.00145	CcSEcCtD
Apraclonidine—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.00144	0.00145	CcSEcCtD
Apraclonidine—Nervousness—Lamivudine—acquired immunodeficiency syndrome	0.00144	0.00145	CcSEcCtD
Apraclonidine—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.00144	0.00145	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.00144	0.00145	CcSEcCtD
Apraclonidine—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.00143	0.00144	CcSEcCtD
Apraclonidine—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.00143	0.00144	CcSEcCtD
Apraclonidine—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.00143	0.00144	CcSEcCtD
Apraclonidine—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.00143	0.00144	CcSEcCtD
Apraclonidine—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.00143	0.00144	CcSEcCtD
Apraclonidine—Infection—Delavirdine—acquired immunodeficiency syndrome	0.00142	0.00143	CcSEcCtD
Apraclonidine—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.00142	0.00143	CcSEcCtD
Apraclonidine—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.00142	0.00143	CcSEcCtD
Apraclonidine—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.00142	0.00143	CcSEcCtD
Apraclonidine—Headache—Didanosine—acquired immunodeficiency syndrome	0.00141	0.00142	CcSEcCtD
Apraclonidine—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.00141	0.00142	CcSEcCtD
Apraclonidine—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.00141	0.00141	CcSEcCtD
Apraclonidine—Malaise—Saquinavir—acquired immunodeficiency syndrome	0.0014	0.00141	CcSEcCtD
Apraclonidine—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.0014	0.00141	CcSEcCtD
Apraclonidine—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.0014	0.00141	CcSEcCtD
Apraclonidine—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.0014	0.00141	CcSEcCtD
Apraclonidine—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.0014	0.0014	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.00139	0.0014	CcSEcCtD
Apraclonidine—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.00139	0.00139	CcSEcCtD
Apraclonidine—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.00139	0.00139	CcSEcCtD
Apraclonidine—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.00138	0.00139	CcSEcCtD
Apraclonidine—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.00138	0.00139	CcSEcCtD
Apraclonidine—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.00138	0.00139	CcSEcCtD
Apraclonidine—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	0.00138	0.00139	CcSEcCtD
Apraclonidine—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.00138	0.00138	CcSEcCtD
Apraclonidine—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.00138	0.00138	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.00137	0.00138	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.00136	0.00137	CcSEcCtD
Apraclonidine—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.00136	0.00137	CcSEcCtD
Apraclonidine—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.00136	0.00137	CcSEcCtD
Apraclonidine—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.00136	0.00137	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.00136	0.00137	CcSEcCtD
Apraclonidine—Pain—Indinavir—acquired immunodeficiency syndrome	0.00135	0.00136	CcSEcCtD
Apraclonidine—Constipation—Indinavir—acquired immunodeficiency syndrome	0.00135	0.00136	CcSEcCtD
Apraclonidine—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.00135	0.00136	CcSEcCtD
Apraclonidine—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.00135	0.00135	CcSEcCtD
Apraclonidine—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.00134	0.00135	CcSEcCtD
Apraclonidine—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.00134	0.00135	CcSEcCtD
Apraclonidine—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.00134	0.00135	CcSEcCtD
Apraclonidine—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.00134	0.00135	CcSEcCtD
Apraclonidine—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.00134	0.00134	CcSEcCtD
Apraclonidine—Nausea—Didanosine—acquired immunodeficiency syndrome	0.00134	0.00134	CcSEcCtD
Apraclonidine—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.00133	0.00134	CcSEcCtD
Apraclonidine—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.00133	0.00134	CcSEcCtD
Apraclonidine—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.00133	0.00133	CcSEcCtD
Apraclonidine—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.00133	0.00133	CcSEcCtD
Apraclonidine—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.00133	0.00133	CcSEcCtD
Apraclonidine—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.00132	0.00133	CcSEcCtD
Apraclonidine—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.00132	0.00132	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.00132	0.00132	CcSEcCtD
Apraclonidine—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.00131	0.00132	CcSEcCtD
Apraclonidine—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.0013	0.00131	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.0013	0.00131	CcSEcCtD
Apraclonidine—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.0013	0.0013	CcSEcCtD
Apraclonidine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.0013	0.0013	CcSEcCtD
Apraclonidine—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.00129	0.0013	CcSEcCtD
Apraclonidine—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.00129	0.0013	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.00129	0.0013	CcSEcCtD
Apraclonidine—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.00129	0.0013	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.00129	0.0013	CcSEcCtD
Apraclonidine—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.00129	0.00129	CcSEcCtD
Apraclonidine—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.00129	0.00129	CcSEcCtD
Apraclonidine—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.00128	0.00129	CcSEcCtD
Apraclonidine—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.00128	0.00129	CcSEcCtD
Apraclonidine—Pain—Efavirenz—acquired immunodeficiency syndrome	0.00128	0.00128	CcSEcCtD
Apraclonidine—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.00128	0.00128	CcSEcCtD
Apraclonidine—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.00127	0.00128	CcSEcCtD
Apraclonidine—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.00127	0.00128	CcSEcCtD
Apraclonidine—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.00127	0.00128	CcSEcCtD
Apraclonidine—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.00127	0.00128	CcSEcCtD
Apraclonidine—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.00127	0.00128	CcSEcCtD
Apraclonidine—Headache—Nevirapine—acquired immunodeficiency syndrome	0.00127	0.00127	CcSEcCtD
Apraclonidine—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.00126	0.00127	CcSEcCtD
Apraclonidine—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.00126	0.00127	CcSEcCtD
Apraclonidine—Infection—Saquinavir—acquired immunodeficiency syndrome	0.00126	0.00127	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.00126	0.00126	CcSEcCtD
Apraclonidine—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.00125	0.00126	CcSEcCtD
Apraclonidine—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.00125	0.00126	CcSEcCtD
Apraclonidine—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.00125	0.00125	CcSEcCtD
Apraclonidine—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.00125	0.00125	CcSEcCtD
Apraclonidine—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.00124	0.00125	CcSEcCtD
Apraclonidine—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.00124	0.00124	CcSEcCtD
Apraclonidine—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.00123	0.00124	CcSEcCtD
Apraclonidine—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.00123	0.00124	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.00123	0.00124	CcSEcCtD
Apraclonidine—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.00123	0.00124	CcSEcCtD
Apraclonidine—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.00123	0.00124	CcSEcCtD
Apraclonidine—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.00123	0.00124	CcSEcCtD
Apraclonidine—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.00123	0.00123	CcSEcCtD
Apraclonidine—Headache—Stavudine—acquired immunodeficiency syndrome	0.00122	0.00123	CcSEcCtD
Apraclonidine—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.00122	0.00123	CcSEcCtD
Apraclonidine—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.00122	0.00123	CcSEcCtD
Apraclonidine—Pain—Delavirdine—acquired immunodeficiency syndrome	0.00122	0.00123	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.00122	0.00123	CcSEcCtD
Apraclonidine—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.00122	0.00123	CcSEcCtD
Apraclonidine—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.00121	0.00122	CcSEcCtD
Apraclonidine—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.00121	0.00122	CcSEcCtD
Apraclonidine—Headache—Abacavir—acquired immunodeficiency syndrome	0.00121	0.00121	CcSEcCtD
Apraclonidine—Infection—Lamivudine—acquired immunodeficiency syndrome	0.0012	0.00121	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.0012	0.00121	CcSEcCtD
Apraclonidine—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.0012	0.00121	CcSEcCtD
Apraclonidine—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.0012	0.00121	CcSEcCtD
Apraclonidine—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.00119	0.0012	CcSEcCtD
Apraclonidine—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.00119	0.0012	CcSEcCtD
Apraclonidine—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.00119	0.00119	CcSEcCtD
Apraclonidine—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.00118	0.00119	CcSEcCtD
Apraclonidine—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.00118	0.00118	CcSEcCtD
Apraclonidine—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.00118	0.00118	CcSEcCtD
Apraclonidine—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.00118	0.00118	CcSEcCtD
Apraclonidine—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.00117	0.00118	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.00117	0.00117	CcSEcCtD
Apraclonidine—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.00116	0.00117	CcSEcCtD
Apraclonidine—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.00116	0.00117	CcSEcCtD
Apraclonidine—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.00116	0.00117	CcSEcCtD
Apraclonidine—Nausea—Stavudine—acquired immunodeficiency syndrome	0.00116	0.00117	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.00116	0.00116	CcSEcCtD
Apraclonidine—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.00115	0.00116	CcSEcCtD
Apraclonidine—Nausea—Abacavir—acquired immunodeficiency syndrome	0.00114	0.00115	CcSEcCtD
Apraclonidine—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.00114	0.00115	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.00114	0.00115	CcSEcCtD
Apraclonidine—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.00114	0.00114	CcSEcCtD
Apraclonidine—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.00113	0.00114	CcSEcCtD
Apraclonidine—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.00113	0.00114	CcSEcCtD
Apraclonidine—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.00113	0.00114	CcSEcCtD
Apraclonidine—Pain—Ritonavir—acquired immunodeficiency syndrome	0.00113	0.00114	CcSEcCtD
Apraclonidine—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.00113	0.00114	CcSEcCtD
Apraclonidine—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.00113	0.00113	CcSEcCtD
Apraclonidine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.00112	0.00113	CcSEcCtD
Apraclonidine—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.00112	0.00112	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.0011	0.00111	CcSEcCtD
Apraclonidine—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.0011	0.00111	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.0011	0.0011	CcSEcCtD
Apraclonidine—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.0011	0.0011	CcSEcCtD
Apraclonidine—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.0011	0.0011	CcSEcCtD
Apraclonidine—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.00109	0.00109	CcSEcCtD
Apraclonidine—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.00109	0.00109	CcSEcCtD
Apraclonidine—Pain—Saquinavir—acquired immunodeficiency syndrome	0.00109	0.00109	CcSEcCtD
Apraclonidine—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.00109	0.00109	CcSEcCtD
Apraclonidine—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.00108	0.00109	CcSEcCtD
Apraclonidine—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.00108	0.00109	CcSEcCtD
Apraclonidine—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.00108	0.00109	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.00108	0.00109	CcSEcCtD
Apraclonidine—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.00108	0.00108	CcSEcCtD
Apraclonidine—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.00107	0.00108	CcSEcCtD
Apraclonidine—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.00107	0.00108	CcSEcCtD
Apraclonidine—Headache—Zidovudine—acquired immunodeficiency syndrome	0.00106	0.00107	CcSEcCtD
Apraclonidine—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.00106	0.00106	CcSEcCtD
Apraclonidine—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.00105	0.00106	CcSEcCtD
Apraclonidine—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.00105	0.00105	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.00105	0.00105	CcSEcCtD
Apraclonidine—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.00104	0.00105	CcSEcCtD
Apraclonidine—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.00104	0.00105	CcSEcCtD
Apraclonidine—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.00104	0.00105	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.00104	0.00104	CcSEcCtD
Apraclonidine—Pain—Lamivudine—acquired immunodeficiency syndrome	0.00104	0.00104	CcSEcCtD
Apraclonidine—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.00104	0.00104	CcSEcCtD
Apraclonidine—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.00102	0.00103	CcSEcCtD
Apraclonidine—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.00102	0.00103	CcSEcCtD
Apraclonidine—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.00101	0.00102	CcSEcCtD
Apraclonidine—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.00101	0.00101	CcSEcCtD
Apraclonidine—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.001	0.00101	CcSEcCtD
Apraclonidine—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.001	0.00101	CcSEcCtD
Apraclonidine—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000999	0.001	CcSEcCtD
Apraclonidine—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000995	0.001	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000991	0.000997	CcSEcCtD
Apraclonidine—Headache—Indinavir—acquired immunodeficiency syndrome	0.000989	0.000995	CcSEcCtD
Apraclonidine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000987	0.000992	CcSEcCtD
Apraclonidine—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000977	0.000982	CcSEcCtD
Apraclonidine—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000973	0.000978	CcSEcCtD
Apraclonidine—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000958	0.000964	CcSEcCtD
Apraclonidine—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000949	0.000954	CcSEcCtD
Apraclonidine—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000947	0.000953	CcSEcCtD
Apraclonidine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000944	0.000949	CcSEcCtD
Apraclonidine—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.00094	0.000945	CcSEcCtD
Apraclonidine—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000938	0.000943	CcSEcCtD
Apraclonidine—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000936	0.000941	CcSEcCtD
Apraclonidine—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000935	0.00094	CcSEcCtD
Apraclonidine—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000934	0.000939	CcSEcCtD
Apraclonidine—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000912	0.000917	CcSEcCtD
Apraclonidine—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000908	0.000913	CcSEcCtD
Apraclonidine—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000903	0.000908	CcSEcCtD
Apraclonidine—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000899	0.000904	CcSEcCtD
Apraclonidine—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000899	0.000904	CcSEcCtD
Apraclonidine—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000894	0.000899	CcSEcCtD
Apraclonidine—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000893	0.000898	CcSEcCtD
Apraclonidine—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000886	0.000891	CcSEcCtD
Apraclonidine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000873	0.000878	CcSEcCtD
Apraclonidine—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.00087	0.000875	CcSEcCtD
Apraclonidine—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000869	0.000874	CcSEcCtD
Apraclonidine—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000857	0.000862	CcSEcCtD
Apraclonidine—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000848	0.000853	CcSEcCtD
Apraclonidine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.00084	0.000845	CcSEcCtD
Apraclonidine—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000839	0.000844	CcSEcCtD
Apraclonidine—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000831	0.000836	CcSEcCtD
Apraclonidine—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000829	0.000834	CcSEcCtD
Apraclonidine—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000827	0.000832	CcSEcCtD
Apraclonidine—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000808	0.000812	CcSEcCtD
Apraclonidine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000801	0.000806	CcSEcCtD
Apraclonidine—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.0008	0.000805	CcSEcCtD
Apraclonidine—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000796	0.000801	CcSEcCtD
Apraclonidine—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000784	0.000789	CcSEcCtD
Apraclonidine—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000771	0.000775	CcSEcCtD
Apraclonidine—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000763	0.000768	CcSEcCtD
Apraclonidine—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000759	0.000764	CcSEcCtD
Apraclonidine—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000755	0.000759	CcSEcCtD
Apraclonidine—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.00072	0.000724	CcSEcCtD
Apraclonidine—ADRA2C—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	8.25e-05	0.0142	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	7.22e-05	0.0124	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	7.03e-05	0.0121	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	6.7e-05	0.0115	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	6.57e-05	0.0113	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	6.36e-05	0.0109	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	5.94e-05	0.0102	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	5.74e-05	0.00989	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	5.35e-05	0.00922	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	5.33e-05	0.00919	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	5.19e-05	0.00894	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	5e-05	0.00861	CbGpPWpGaD
Apraclonidine—ADRA2B—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	4.94e-05	0.00851	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	4.84e-05	0.00834	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	4.82e-05	0.00831	CbGpPWpGaD
Apraclonidine—ADRA2B—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	4.64e-05	0.008	CbGpPWpGaD
Apraclonidine—ADRA2B—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	4.64e-05	0.008	CbGpPWpGaD
Apraclonidine—ADRA2C—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	4.61e-05	0.00795	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	4.58e-05	0.0079	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	4.53e-05	0.00781	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	4.52e-05	0.00779	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	4.37e-05	0.00753	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	4.34e-05	0.00748	CbGpPWpGaD
Apraclonidine—ADRA2C—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	4.34e-05	0.00747	CbGpPWpGaD
Apraclonidine—ADRA2C—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	4.34e-05	0.00747	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	4.31e-05	0.00742	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	4.28e-05	0.00738	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	4.24e-05	0.00729	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	4.06e-05	0.007	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	4.06e-05	0.00699	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	4.03e-05	0.00693	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	3.95e-05	0.00681	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	3.93e-05	0.00676	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	3.75e-05	0.00646	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	3.74e-05	0.00645	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	3.7e-05	0.00638	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	3.69e-05	0.00636	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	3.69e-05	0.00636	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	3.67e-05	0.00633	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	3.67e-05	0.00632	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	3.66e-05	0.0063	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	3.55e-05	0.00611	CbGpPWpGaD
Apraclonidine—ADRA2B—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	3.53e-05	0.00609	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	3.52e-05	0.00607	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	3.52e-05	0.00607	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	3.52e-05	0.00606	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	3.48e-05	0.00599	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	3.45e-05	0.00594	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	3.45e-05	0.00594	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	3.44e-05	0.00593	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	3.42e-05	0.00588	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.31e-05	0.0057	CbGpPWpGaD
Apraclonidine—ADRA2C—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	3.3e-05	0.00568	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	3.3e-05	0.00568	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	3.27e-05	0.00563	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	3.21e-05	0.00552	CbGpPWpGaD
Apraclonidine—ADRA2B—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	3.18e-05	0.00548	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.09e-05	0.00532	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	3.02e-05	0.00519	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	3.02e-05	0.00519	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.99e-05	0.00515	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	2.98e-05	0.00513	CbGpPWpGaD
Apraclonidine—ADRA2C—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	2.97e-05	0.00512	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.95e-05	0.00509	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.81e-05	0.00484	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.81e-05	0.00484	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.81e-05	0.00484	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	2.8e-05	0.00483	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	2.8e-05	0.00483	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.79e-05	0.00481	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	2.77e-05	0.00478	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.76e-05	0.00475	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.75e-05	0.00473	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	2.7e-05	0.00465	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	2.68e-05	0.00462	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.68e-05	0.00461	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—TAT—acquired immunodeficiency syndrome	2.67e-05	0.00459	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.63e-05	0.00452	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.63e-05	0.00452	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.62e-05	0.00452	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.57e-05	0.00442	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.53e-05	0.00436	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	2.51e-05	0.00432	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.5e-05	0.00431	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.48e-05	0.00428	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.44e-05	0.00421	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	2.42e-05	0.00416	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.41e-05	0.00415	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—IFNA1—acquired immunodeficiency syndrome	2.41e-05	0.00415	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	2.38e-05	0.0041	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.36e-05	0.00407	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.32e-05	0.004	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.3e-05	0.00395	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.3e-05	0.00395	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.29e-05	0.00395	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.27e-05	0.00391	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AGPS—acquired immunodeficiency syndrome	2.27e-05	0.00391	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—IFNA1—acquired immunodeficiency syndrome	2.25e-05	0.00387	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.24e-05	0.00386	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.24e-05	0.00386	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	2.23e-05	0.00383	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.19e-05	0.00377	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—TAT—acquired immunodeficiency syndrome	2.17e-05	0.00373	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.14e-05	0.00368	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.13e-05	0.00367	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.13e-05	0.00367	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.13e-05	0.00367	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.08e-05	0.00359	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.07e-05	0.00356	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.03e-05	0.0035	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.03e-05	0.00349	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2e-05	0.00344	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.93e-05	0.00333	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.93e-05	0.00332	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.92e-05	0.00331	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.89e-05	0.00325	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.88e-05	0.00325	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AGPS—acquired immunodeficiency syndrome	1.84e-05	0.00317	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—IFNA1—acquired immunodeficiency syndrome	1.83e-05	0.00315	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	1.81e-05	0.00311	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.8e-05	0.00311	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.8e-05	0.0031	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.76e-05	0.00303	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.75e-05	0.00301	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.7e-05	0.00292	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.69e-05	0.00291	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.62e-05	0.0028	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.62e-05	0.0028	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.62e-05	0.0028	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.59e-05	0.00274	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.59e-05	0.00274	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.59e-05	0.00273	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.58e-05	0.00272	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.57e-05	0.00271	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.54e-05	0.00264	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.52e-05	0.00261	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.52e-05	0.00261	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.48e-05	0.00256	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.48e-05	0.00256	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.47e-05	0.00253	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.47e-05	0.00252	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.46e-05	0.00252	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.44e-05	0.00249	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.44e-05	0.00249	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.43e-05	0.00247	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.43e-05	0.00246	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.39e-05	0.00239	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.38e-05	0.00238	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.37e-05	0.00236	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.35e-05	0.00232	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.35e-05	0.00232	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.33e-05	0.00228	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.33e-05	0.00228	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.3e-05	0.00224	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.3e-05	0.00224	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.29e-05	0.00222	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.28e-05	0.00221	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.25e-05	0.00216	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.23e-05	0.00212	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.23e-05	0.00212	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—ALB—acquired immunodeficiency syndrome	1.23e-05	0.00212	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.21e-05	0.00208	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.21e-05	0.00208	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.21e-05	0.00208	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.2e-05	0.00206	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.19e-05	0.00205	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.18e-05	0.00203	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.18e-05	0.00203	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.16e-05	0.00201	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—ALB—acquired immunodeficiency syndrome	1.15e-05	0.00198	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.13e-05	0.00195	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.11e-05	0.00192	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.11e-05	0.00192	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.1e-05	0.00189	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.1e-05	0.00189	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.1e-05	0.00189	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.09e-05	0.00188	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.08e-05	0.00186	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.03e-05	0.00177	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.02e-05	0.00175	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.01e-05	0.00174	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1e-05	0.00173	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—IL2—acquired immunodeficiency syndrome	9.96e-06	0.00172	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	9.89e-06	0.0017	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	9.87e-06	0.0017	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	9.73e-06	0.00167	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	9.48e-06	0.00163	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	9.37e-06	0.00161	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—ALB—acquired immunodeficiency syndrome	9.32e-06	0.0016	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—IL2—acquired immunodeficiency syndrome	9.3e-06	0.0016	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	9.24e-06	0.00159	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	9.17e-06	0.00158	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.07e-06	0.00156	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	9.04e-06	0.00156	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	8.97e-06	0.00154	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	8.89e-06	0.00153	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	8.83e-06	0.00152	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.53e-06	0.00147	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.53e-06	0.00147	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.47e-06	0.00146	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	8.33e-06	0.00143	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	8.26e-06	0.00142	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	8.21e-06	0.00141	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	8.19e-06	0.00141	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	8.08e-06	0.00139	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.96e-06	0.00137	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.96e-06	0.00137	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7.61e-06	0.00131	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—IL2—acquired immunodeficiency syndrome	7.56e-06	0.0013	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	7.5e-06	0.00129	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.4e-06	0.00128	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.96e-06	0.0012	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.96e-06	0.0012	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	6.88e-06	0.00118	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.49e-06	0.00112	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.47e-06	0.00111	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.47e-06	0.00111	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.39e-06	0.0011	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.29e-06	0.00108	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.06e-06	0.00104	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.97e-06	0.00103	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.88e-06	0.00101	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.84e-06	0.00101	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.72e-06	0.000984	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.46e-06	0.00094	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.34e-06	0.000919	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.3e-06	0.000912	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.22e-06	0.000898	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.14e-06	0.000885	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.92e-06	0.000847	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.85e-06	0.000835	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.78e-06	0.000822	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.77e-06	0.000822	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.67e-06	0.000804	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ALB—acquired immunodeficiency syndrome	4.65e-06	0.000801	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.43e-06	0.000764	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.34e-06	0.000747	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ALB—acquired immunodeficiency syndrome	3.78e-06	0.000651	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.38e-06	0.000581	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.36e-06	0.000579	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.15e-06	0.000543	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.14e-06	0.00054	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.76e-06	0.000475	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.74e-06	0.000472	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.56e-06	0.000441	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.55e-06	0.000439	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.98e-06	0.000342	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.85e-06	0.000319	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.62e-06	0.000279	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.51e-06	0.000259	CbGpPWpGaD
